1. Home
  2. MBBC vs MDXH Comparison

MBBC vs MDXH Comparison

Compare MBBC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBBC

Marathon Bancorp Inc.

HOLD

Current Price

$15.49

Market Cap

43.4M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.44

Market Cap

41.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBBC
MDXH
Founded
1902
2003
Country
United States
Belgium
Employees
35
N/A
Industry
Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
41.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MBBC
MDXH
Price
$15.49
$0.44
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
21.4K
758.2K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
$47.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.96
$0.45
52 Week High
$15.75
$5.33

Technical Indicators

Market Signals
Indicator
MBBC
MDXH
Relative Strength Index (RSI) 63.55 18.95
Support Level $12.90 N/A
Resistance Level $15.55 $3.79
Average True Range (ATR) 0.79 0.05
MACD 0.10 0.04
Stochastic Oscillator 96.41 11.12

Price Performance

Historical Comparison
MBBC
MDXH

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: